A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings, published ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from ...

Targeting clonal antigens and circumventing dysfunctional states may be important for conferring clinical responses to TIL therapy.